Artículo

Colony-stimulating factor-1 receptor inhibition attenuates microgliosis and myelin loss but exacerbates neurodegeneration in the chronic cuprizone model

Wies Mancini, Victoria Sofia Berenice Icon; Di Pietro, Anabella Ayelen ; de Olmos, Soledad Icon; Silva Pinto, Pablo Roberto Icon; Vence, Marianela Icon; Marder, Nora Mariel Icon; Müller Igaz, Lionel Ivan Icon; Marcora, Maria Silvina Icon; Pasquini, Juana Maria Icon; Correale, Jorge ; Pasquini, Laura Andrea Icon

Otros responsables

Fecha

12/2021

Editorial

Wiley Blackwell Publishing, Inc

Revista

Journal of Neurochemistry

Título del libro

Nombre del evento

Fecha del evento

Institución organizadora

ISSN

0022-3042

eISSN

1471-4159

ISBN

Idioma

Inglés

Tipo del evento

Clasificación temática

Resumen

Multiple sclerosis (MS), especially in its progressive phase, involves early axonal and neuronal damage resulting from a combination of inflammatory mediators, demyelination, and loss of trophic support. During progressive disease stages, a microenvironment is created within the central nervous system (CNS) favoring the arrival and retention of inflammatory cells. Active demyelination and neurodegeneration have also been linked to microglia (MG) and astrocyte (AST)-activation in early lesions. While reactive MG can damage tissue, exacerbate deleterious effects, and contribute to neurodegeneration, it should be noted that activated MG possess neuroprotective functions as well, including debris phagocytosis and growth factor secretion. The progressive form of MS can be modeled by the prolonged administration to cuprizone (CPZ) in adult mice, as CPZ induces highly reproducible demyelination of different brain regions through oligodendrocyte (OLG) apoptosis, accompanied by MG and AST activation and axonal damage. Therefore, our goal was to evaluate the effects of a reduction in microglial activation through orally administered brain-penetrant colony-stimulating factor-1 receptor (CSF-1R) inhibitor BLZ945 (BLZ) on neurodegeneration and its correlation with demyelination, astroglial activation, and behavior in a chronic CPZ-induced demyelination model. Our results show that BLZ treatment successfully reduced the microglial population and myelin loss. However, no correlation was found between myelin preservation and neurodegeneration, as axonal degeneration was more prominent upon BLZ treatment. Concomitantly, BLZ failed to significantly offset CPZ-induced astroglial activation and behavioral alterations. These results should be taken into account when proposing the modulation of microglial activation in the design of therapies relevant for demyelinating diseases. (Figure presented.). Cover Image for this issue: https://doi.org/10.1111/jnc.15394.

Aprobación

Revisión

Complementado por

Referenciado por

Licencia Creative Commons

Excepto donde se indique lo contrario, la licencia de este ítem se describe como by-nc-sa